Combined Early and Late [⁶⁸Ga]PSMA-HBED-CC PET Scans Improve Lesion Detectability in Biochemical Recurrence of...

Our aim was to evaluate the benefit of early (1 h post-injection (p.i.)) and late (3 h p.i.) [⁶⁸Ga]PSMA-HBED-CC positron emission tomography (PET)/x-ray computed tomography (CT) imaging for detection of biochemical recurrence (BCR) of prostate cancer (PCa).

Seventy patients with BCR of the PCa and prostate-specific antigen (PSA) levels of less than 2.0 μg/l were subjected to [⁶⁸Ga]PSMA-HBED-CC PET (mean injected activity 180 MBq). While early imaging contained whole body scans, late imaging was confined to the pelvis and the lower abdomen. Uptake in suspicious lesions was analyzed by peak and maximum standardized uptake values (SUV_peak/max). Tumor-to-background ratios were calculated for all lesions in which the liver served as reference organ. The Wilcoxon matched-pair signed-rank test was used to compare the uptake in suspicious lesions between early and late imaging. Follow-up data were used to validate the existence of the additionally detected lesions.

Forty-four of the 70 patients thus examined were interpreted as PSMA-positive in early and/or late scans while 26 remained without suspicion of PSMA tracer uptake. A total of 70 suspicious lesions were analyzed. Ten tumor-suspicious lesions from seven different patients were better or exclusively visible in the late measurements while three tumor-suspicious lesions from three different patients were better or exclusively visible in the early images. A validation by follow-up data was possible for 11 of these 13 additionally detected lesions. In direct comparison between early and late imaging, the mean SUV_max in PSMA-positive lesions was 74 % higher (p < 0.001) and the mean SUV_peak was 36 % higher (p = 0.001) in the late scans. The SUV_mean in the reference regions was decreasing in the late measurements, whereas the mean TBR increased by a factor of 3 (p < 0.001). Taking confirmed lesions only into account, we estimated a 10 % gain in additionally detected PSMA-positive lesions (7/70) within the patient cohort.

The time period between injection and data acquisition influences the detection rate of [⁶⁸Ga]PSMA-HBED-CC PET/CT. In biochemical recurrence with low PSA levels, late [⁶⁸Ga]PSMA-HBED-CC PET/CT imaging offers frequent advantages with regard to lesion contrast.